Core Viewpoint - The Chinese pharmaceutical industry is expected to continue its upward trend due to positive factors such as the overseas expansion of innovative drugs and the optimization of domestic procurement policies [1] Group 1: Industry Outlook - The report from招商国际 indicates that the market has high expectations for the frequency and scale of overseas transactions, leading to a sustained increase in the valuation of innovative drugs [1] - The future growth of innovative drugs is anticipated to be driven primarily by the clinical advancement of authorized pipelines by overseas partners [1] Group 2: Company Recommendations - The report recommends buying shares in the following companies: 三生制药 (01530), 巨子生物 (02367), 药明合联 (02268), 固生堂 (02273), 中国生物制药 (01177), and 信达生物 (01801) [1]

4 September 2025 | 8:51PM HKT Innovent Biologics (1801.HK): Asia Leaders Conference 2025 — Key Takeaways: Glucagon as key moat for mazdutide; Aiming for full global Bottom line: Management shared: 1) glucagon will be the key differentiator for mazdutide to build a competitive moat, 2) three-step plan for IBI363 indication expansion, and 3) aim to build full-chain global capabilities with the first ph3 MRCT as the starting point. Key takeaways: Goldman Sachs does and seeks to do business with companies cover ...

Group 1: Gold Market Analysis - Recent surge in gold prices, with London gold reaching nearly $3580 per ounce on September 3, 2025, after a four-month period of high volatility [12][10] - Under neutral assumptions, the gold price midpoint for the second half of the year is projected at $3627 per ounce, with an optimistic scenario suggesting a rise to $3816 per ounce [12][10] - Key drivers for the recent price increase include a shift in investment from long-term US and European bonds to gold due to concerns over debt risks, particularly in Europe [12][11] Group 2: International Beauty Market Trends - The global beauty market is expected to grow at a rate of 4.5% in 2024, down from 8% in 2023, with significant regional disparities [13][13] - The European market outperformed the global average with a 7.5% year-on-year growth, while the North Asia market saw a decline of 2% [13][13] - Major international beauty brands are adapting to the competitive landscape in China by embracing new online channels and local partnerships, leading to a slight recovery in market performance [13][13] Group 3: Fourth Paradigm Company Overview - The company is projected to achieve revenues of 68.52 billion, 88.19 billion, and 112.26 billion yuan from 2025 to 2027, with year-on-year growth rates of 30%, 29%, and 27% respectively [17][17] - The company is expected to turn a profit by 2025, with net profits forecasted at 0.55 billion, 2.83 billion, and 5.68 billion yuan for the same period [17][17] - The company's strategy focuses on standardization, which is anticipated to drive rapid industry expansion and maintain long-term competitiveness [14][14]

Core Viewpoint - Innovent Biologics announced positive results from the Phase 2 clinical study of tigulixostat, a xanthine oxidase inhibitor, showing superior urate-lowering efficacy compared to febuxostat in Chinese gout patients, leading to plans for a Phase 3 study in late 2025 [1][7][12]. Group 1: Clinical Study Results - The Phase 2 study involved 84 participants with a mean age of 37 years and a mean baseline serum uric acid level of 575 μmol/L (9.6 mg/dL) [3]. - At week 16, the proportion of participants achieving serum uric acid (sUA) levels below 360 μmol/L (6 mg/dL) was significantly higher in the tigulixostat groups: 55.0% for 50 mg, 81.0% for 100 mg, and 85.7% for 200 mg, compared to 18.2% for febuxostat [6]. - The percent change in sUA from baseline was -38.66% for the 50 mg group, -48.61% for the 100 mg group, and -57.11% for the 200 mg group, while febuxostat showed a change of -24.11% [6]. Group 2: Safety Profile - Tigulixostat exhibited a favorable safety profile with no increased risk of renal impairment and similar incidence of adverse events across groups, all of which were mild to moderate [6][12]. - No serious adverse events were reported, and the incidence of gout flare was comparable between tigulixostat and febuxostat groups [6]. Group 3: Market Context and Need - Gout and hyperuricemia are increasingly recognized as major chronic diseases, with a prevalence of hyperuricemia in China at 13.3%, affecting approximately 15.5 million gout patients [5]. - Current treatments like allopurinol and febuxostat have significant safety concerns, highlighting the urgent need for safer and more effective options [10][12]. Group 4: Future Development Plans - Based on the positive Phase 2 results, Innovent plans to accelerate the Phase 3 clinical development of tigulixostat to provide new treatment options for gout patients in China [7][12]. - The company is committed to advancing its pipeline in cardiovascular and metabolic diseases, addressing a broad population affected by related conditions [7].

Core Viewpoint - The report emphasizes the sustained high growth in the innovative pharmaceutical and medical device sectors, recommending continued investment in these areas [1]. Investment Highlights - The report maintains a recommendation for innovative pharmaceuticals and medical devices, highlighting the potential for value re-evaluation in the Pharma sector, with specific buy ratings for companies such as 恒瑞医药, 翰森制药, 三生制药, and 华东医药 [2]. - It continues to recommend Biopharma/Biotech companies that are gradually realizing their innovative pipelines and entering a performance growth phase, with buy ratings for 科伦博泰生物, 信达生物, 康方生物, 新诺威, 映恩生物, 京新药业, 微芯生物, 特宝生物, 我武生物, and 来凯医药 [2]. - The report also suggests investment in CXO and upstream pharmaceutical companies benefiting from innovation and recovery, maintaining buy ratings for 百普赛斯, 药明康德, 药明合联, 泰格医药, and 美诺华 [2]. - It recommends leading medical device companies expected to recover, with buy ratings for 微创医疗, 联影医疗, and 惠泰医疗 [2]. Market Performance - In the first week of September 2025, the A-share pharmaceutical sector outperformed the broader market, with the SW pharmaceutical and biotech index rising by 1.4% while the Shanghai Composite Index fell by 1.2% [3]. - Within the biopharmaceutical sector, the chemical preparations segment saw a notable increase of 4.5%, while biological products and medical services rose by 1.9% and 1.7%, respectively [3]. - The top-performing stocks included 海辰药业 (+28.7%), 长春高新 (+24.2%), and 百花医药 (+21.3%), while the worst performers were 舒泰神 (-24.0%), 广生堂 (-15.8%), and 塞力医疗 (-15.6%) [3]. - In the Hong Kong market, the healthcare sector also outperformed, with the Hang Seng Healthcare index rising by 7.0% and the biotech index by 7.3%, compared to a 1.4% increase in the Hang Seng Index [3]. - The top gainers in the Hong Kong market were 三叶草生物-B (+99%), 圣诺医药-B (+62%), and 加科思-B (+41%), while the biggest losers included 美中嘉和 (-11%), 科笛-B (-9%), and 思路迪医药股份 (-6%) [3]. - In the US market, the healthcare sector performed in line with the broader market, with the S&P Healthcare Select Sector Index increasing by 0.3%, matching the S&P 500's performance [4]. - The top gainers in the US healthcare sector included 德康医疗 (+7%), 生物基因 (+6%), and 环球健康服务 (+5%), while the largest declines were seen in KENVUE (-10%), REVVITY (-4%), and MOLINA HEALTHCARE (-3%) [4].

Group 1: Market Overview - The Hong Kong capital market is expected to see a significant recovery in 2025, with IPO financing reaching HKD 132.9 billion in the first eight months, a 50% increase compared to the total for 2024 [1] - The secondary market for Hong Kong stock offerings is performing even stronger, raising HKD 190.5 billion, which is 3.8 times higher than the total for 2024, with an average fundraising size of HKD 1.1 billion per project [1] Group 2: Underwriting Market Characteristics - The underwriting market for Hong Kong stock offerings in 2025 shows a "head concentration and foreign capital leading" characteristic, with six out of the top ten underwriters being foreign investment banks [3] - The top six underwriters have all surpassed HKD 15 billion in underwriting scale, collectively accounting for over 70% of the overall market [3] Group 3: Top Underwriters - Goldman Sachs leads the underwriting market with a scale of HKD 39.5 billion, holding a market share of approximately 21%, and has a strong focus on "head large projects" [5] - CITIC Securities ranks second with HKD 24.8 billion, but its underwriting structure is heavily reliant on a single large project, which limits its overall project diversity [6] - UBS ranks third with HKD 24.1 billion, demonstrating a balanced approach with both large and small projects, contributing to its competitive position [7] Group 4: Performance Discrepancies - CICC, while being the top underwriter for IPOs, has seen a significant drop in its performance in the secondary market, with only HKD 21.3 billion in underwriting scale, indicating a disconnect in core client cooperation [8][9] - Guotai Junan, despite having the highest number of projects at 27, has a low underwriting scale of HKD 9.7 billion, reflecting its inability to secure large projects [10]

Core Viewpoint - The company reported a significant turnaround in its financial performance for the first half of 2025, achieving a net profit of 8.34 billion yuan compared to a net loss of 3.93 billion yuan in the same period last year, driven by strong product sales and a diverse product pipeline [1][2]. Financial Performance - In H1 2025, the company achieved operating revenue of 59.53 billion yuan, representing a year-on-year increase of 50.6% [1]. - Product sales revenue was 52.34 billion yuan, up 37.3% year-on-year, while licensing fee income was 6.66 billion yuan [1]. Product Pipeline and Development - The company has a robust product matrix, with 16 products approved for market as of H1 2025, including 12 oncology products and 4 general pipeline products [1]. - Two additional products, IBI112 and IBI310, are expected to be approved by the end of 2025, which will further enhance the company's growth potential [1]. Global Collaboration and Market Expansion - The company entered a global collaboration agreement with Roche for the development, production, and commercialization rights of IBI3009 [2]. - Efforts are ongoing to expand market access for approved products in various regions, including Hong Kong, Macau, Southeast Asia, and Latin America [2]. Research and Development Investment - In H1 2025, the company invested 10.09 billion yuan in research and development, maintaining high efficiency and execution in its R&D efforts [2]. Profit Forecast and Valuation - Due to the accelerated product development and better-than-expected sales, the company's net profit forecasts for 2025 and 2026 have been raised to 8.46 billion yuan and 15.72 billion yuan, respectively [2]. - The company is recognized as a leading innovative pharmaceutical enterprise in China, with a strong commercial product portfolio aimed at providing comprehensive solutions for a wider patient demographic [2].

Group 1 - The company reported a revenue of 5.953 billion yuan for the first half of 2025, representing a year-on-year increase of 50.6%, with product revenue at 5.23 billion yuan, up 37.3% [1] - Net profit reached 1.21 billion yuan, driven by the launch of new products and a 666 million yuan upfront payment from Roche [1] - The gross margin was 86.8%, an increase of 2.7 percentage points, while the ratio of selling and administrative expenses decreased by 7.9 percentage points to 44.2% [1] Group 2 - The oncology pipeline is transitioning from a leading position in China to global innovation, with new generation IO+ADC frameworks established [1] - Three new oncology products were launched: Daberu (ROS1 inhibitor), Aoyixin (EGFR TKI), and Jiepal (non-covalent BTK inhibitor) [1] - IBI363 (PD-1/IL-2 dual antibody) showed significant efficacy in three oral reports at ASCO, with multiple registration clinical studies initiated [1] Group 3 - IBI343 (CLDN18.2 ADC) became the first ADC drug to enter Phase III trials for pancreatic cancer globally [2] - Several ADC products, including IBI3009 (DLL3 ADC) and IBI3001 (EGFR/B7H3 ADC), are advancing into global development [2] - The company has multiple major products entering commercialization, including Torelis monoclonal antibody and the first approved dual-target weight loss drug [2] Group 4 - The company is positioned as a leading innovative drug developer in China, with a workforce of 7,500 employees globally [3] - Revenue projections for 2025-2027 are 12.074 billion yuan, 15.046 billion yuan, and 20.584 billion yuan, with growth rates of 28.15%, 24.61%, and 36.81% respectively [3] - Expected net profit for the same period is 939 million yuan, 1.665 billion yuan, and 3.072 billion yuan [3]

Group 1 - In the first eight months of the year, 610 out of 644 comparable QDII funds saw an increase in net value, representing 94.7% of the total [1] - The innovative drug sector has rebounded, leading to significant gains for funds heavily invested in this area, with top performers including Huatai-PB Hong Kong Advantage Selected Mixed C and A, achieving returns of 133.73% and 133.56% respectively [1] - The top ten holdings of Huatai-PB Hong Kong Advantage Selected Mixed A/C include companies such as InnoCare Pharma, Kelun-Biotech, and Innovent Biologics [1] Group 2 - Ten QDII funds recorded gains exceeding 90%, with four from E Fund Management, including E Fund Global Pharmaceutical Industry Mixed Fund, all surpassing 94% [2] - The top ten holdings of these E Fund products include major players like Innovent Biologics and InnoCare Pharma [2] Group 3 - Funds such as GF CSI Hong Kong Innovative Drug ETF and Huatai-PB Hang Seng Innovative Drug ETF also performed well, with returns of 103.70% and 100.04% respectively [3] - The top ten holdings of the larger Huatai-PB Hang Seng Biotechnology ETF include companies like Innovent Biologics and WuXi Biologics [3] Group 4 - The bottom performers among QDII funds primarily tracked the FTSE Saudi Arabia Index, with several oil and gas funds and those tracking the S&P 500 healthcare index also underperforming [4]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年8月31日 | | | 狀態: | 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 信達生物製藥 | | | | | | 呈交日期: | 2025年9月4日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 01801 | 說明 | 普通股 | | | 本月底法定/註冊股本總額： USD 50,000 FF301 第 1 頁 共 11 頁 v 1.1.1 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 5,000,000,000 USD 0.00001 USD 50,000 增加 / 減少 (-) 0 USD 0 本月底結存 5,000,000,000 USD 0.00001 USD 50,000 FF301 II. 已發行股 ...